Philips and icometrix advance precision diagnosis in neurology with innovative AI-based imaging solutions at #RSNA24
Philips and icometrix have partnered to deploy an AI-driven solution for MRI brain scan analysis, focusing on Alzheimer's and multiple sclerosis diagnosis. The solution integrates icometrix's FDA-cleared quantitative brain software into Philips' BlueSeal MR scanners and healthcare informatics platform. The collaboration addresses the growing demand for neurological imaging, particularly with new Alzheimer's treatments requiring multiple MRI scans. The integrated system features icobrain ARIA software for monitoring treatment side effects and icobrain ms for MS diagnosis, offering automated quantitative measurements and improved diagnostic accuracy.
Philips e icometrix hanno stretto una partnership per implementare una soluzione basata sull'IA per l'analisi delle risonanze magnetiche del cervello, con un focus sulla diagnosi dell'Alzheimer e della sclerosi multipla. La soluzione integra il software quantitativo per il cervello, approvato dalla FDA, di icometrix nei scanner MR BlueSeal di Philips e nella piattaforma informatica sanitaria. La collaborazione risponde alla crescente richiesta di imaging neurologico, in particolare con i nuovi trattamenti per l'Alzheimer che richiedono più risonanze magnetiche. Il sistema integrato presenta il software icobrain ARIA per il monitoraggio degli effetti collaterali del trattamento e icobrain ms per la diagnosi della sclerosi multipla, offrendo misurazioni quantitative automatizzate e una maggiore accuratezza diagnostica.
Philips e icometrix han unido fuerzas para desplegar una solución impulsada por IA para el análisis de escaneos cerebrales por MRI, centrándose en el diagnóstico del Alzhéimer y la esclerosis múltiple. La solución integra el software cerebral cuantitativo de icometrix, aprobado por la FDA, en los escáneres MR BlueSeal de Philips y su plataforma de informática sanitaria. La colaboración aborda la creciente demanda de imágenes neurológicas, especialmente con los nuevos tratamientos para el Alzhéimer que requieren múltiples escaneos de MRI. El sistema integrado presenta el software icobrain ARIA para el monitoreo de los efectos secundarios del tratamiento y el icobrain ms para el diagnóstico de la esclerosis múltiple, ofreciendo mediciones cuantitativas automatizadas y una mejora en la precisión diagnóstica.
필립스와 아이코메트릭스가 함께 협력하여 알츠하이머병 및 다발성 경화증 진단을 위한 MRI 뇌 스캔 분석을 위한 AI 기반 솔루션을 배포하고 있습니다. 이 솔루션은 필립스의 BlueSeal MR 스캐너와 의료 정보 솔루션 플랫폼에 FDA 승인을 받은 아이코메트릭스의 정량적 뇌 소프트웨어를 통합합니다. 이러한 협업은 알츠하이머의 새로운 치료법으로 인해 여러 MRI 스캔이 필요하게 되면서 증가하는 신경 영상 수요를 충족하는 데 기여합니다. 통합 시스템은 치료 부작용 모니터링을 위한 icobrain ARIA 소프트웨어와 MS 진단을 위한 icobrain ms를 특징으로 하며, 자동화된 정량적 측정 및 개선된 진단 정확도를 제공합니다.
Philips et icometrix ont établi un partenariat pour déployer une solution basée sur l'IA pour l'analyse des IRM cérébrales, axée sur le diagnostic de la maladie d'Alzheimer et de la sclérose en plaques. La solution intègre le logiciel quantitatif cérébral d'icometrix, approuvé par la FDA, dans les scanners IRM BlueSeal de Philips et leur plateforme d'informatique de santé. Cette collaboration répond à la demande croissante d'imagerie neurologique, en particulier avec les nouveaux traitements de l'Alzheimer nécessitant plusieurs IRM. Le système intégré dispose du logiciel icobrain ARIA pour le suivi des effets secondaires du traitement et de l'icobrain ms pour le diagnostic de la sclérose en plaques, offrant des mesures quantitatives automatisées et une précision diagnostique améliorée.
Philips und icometrix haben sich zusammengeschlossen, um eine KI-gestützte Lösung für die Analyse von MRI-Gehirnscans bereitzustellen, wobei der Schwerpunkt auf der Diagnose von Alzheimer und multipler Sklerose liegt. Die Lösung integriert die von der FDA zugelassene quantitative Gehirnsoftware von icometrix in die BlueSeal-MR-Scanner von Philips und deren Gesundheitsinformatik-Plattform. Die Zusammenarbeit reagiert auf die wachsende Nachfrage nach neurologischer Bildgebung, insbesondere mit neuen Alzheimer-Behandlungen, die mehrere MRI-Scans erfordern. Das integrierte System enthält die icobrain ARIA-Software zur Überwachung von Behandlungsideffekten und icobrain ms zur Diagnose der MS und bietet automatisierte quantitative Messungen sowie eine verbesserte diagnostische Genauigkeit.
- Integration of FDA-cleared AI software enhances diagnostic capabilities
- Solution addresses growing market demand for neurological imaging
- Automated quantitative measurements improve efficiency and accuracy
- System supports monitoring of treatment side effects in Alzheimer's patients
- None.
Insights
The integration of icometrix's AI-powered brain imaging solutions with Philips' MRI systems represents a significant technological advancement in neurological diagnostics. The partnership addresses critical market needs with FDA-cleared solutions for Alzheimer's and MS diagnosis, particularly timely given the growing demand for brain imaging with new Alzheimer's treatments.
The collaboration has substantial commercial potential, driven by the projected increase to 150 million dementia cases by 2050. The solution's ability to automate and quantify brain scan analysis could significantly reduce operational costs and improve efficiency for healthcare providers. The CPT III code reimbursement approval in the US adds a clear revenue pathway.
However, market adoption will depend on healthcare provider integration capabilities and reimbursement policies across different regions. Competition from other AI imaging solutions and potential regulatory challenges could impact growth trajectory.
The technical integration demonstrates sophisticated AI implementation in clinical workflows. Key differentiators include automated ARIA detection for monitoring treatment side effects and the unique FLAIR* imaging capability for MS diagnosis. The cloud-based deployment through Philips AI Manager enables scalable implementation across healthcare networks.
The solution addresses critical bottlenecks in neurological care delivery: staff shortages, standardization of diagnosis and the increasing imaging volume requirements for new Alzheimer's treatments. The automated quantification and reporting features could significantly reduce reading time and improve diagnostic accuracy.
The platform's ability to provide longitudinal analysis and quantitative comparisons positions it well for the growing precision medicine market in neurology.
November 25, 2024
icometrix’ FDA-cleared quantitative brain solution for neurological conditions including Alzheimer’s and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platform
Amsterdam, the Netherlands and Leuven, Belgium – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and computer-aided diagnostics company icometrix (Leuven, Belgium) have teamed up to deploy an AI-driven, end-to-end solution for acquiring, reading, and reporting the results of MRI brain scans to optimize diagnosis and treatment monitoring of neurological conditions including Alzheimer’s and multiple sclerosis (MS). Unveiled at RSNA 2024, icometrix’s unique AI-powered quantitative reporting software is seamlessly integrated into Philips’ latest BlueSeal MR scanners through Philips’ new Smart Reading capability [1], providing consistent and more accurate diagnosis. The software will also be deployed on Philips’ healthcare informatics platform – including Philips cloud-based AI Manager.
The introduction of new drugs that slow the progression of Alzheimer’s emphasizes the critical role of MRI in patient management. By leveraging advanced MRI techniques, neurologists can identify the most suitable candidates for these therapies, ensuring timely and personalized treatment. AI's ability to extract quantitative measurements from brain scans enhances the diagnostic process, enabling quicker decision making and improved monitoring of disease progression. This integration of technology increases efficiency for healthcare providers and leads to more tailored treatment.
“Philips is at the forefront of applying AI to help save time and improve diagnostic accuracy so clinicians can deliver better care to more patients,” said Shez Partovi, Chief Innovation & Strategy Officer at Philips. “As these innovations continue to evolve, they hold great promise for transforming the landscape of neurological care, offering hope for better management of chronic conditions like Alzheimer’s and MS. Our partnership with icometrix is an important step forward in the use of AI to help mitigate staff shortages, lower the cost of care, increase diagnostic confidence, and facilitate care orchestration of personalized plans for the growing number of people who are diagnosed with Alzheimer's disease."
“Our icobrain imaging AI measures are rapidly becoming the standard of care for diagnosis and monitoring of neurological conditions,” said Wim Van Hecke, CEO of icometrix. “MRI quantification is crucial to unlock precision medicine, especially in the Alzheimer’s disease care pathway, which is why our partnership with Philips is so well timed. We have developed the leading AI solutions for brain MRI monitoring, received CPT III code reimbursement in the US, and we will be able to support radiologists, neurologists, and people with neurological conditions at scale through this collaboration.”
Managing the growing volume of Alzheimer’s imaging results
Alzheimer’s is the most common form of dementia, accounting for
In addition to icometrix’s icobrain dm software for differential dementia diagnosis, the solution also includes the company’s icobrain ARIA software [4]. The only FDA-cleared solution that is classified as computer-aided detection and diagnosis, Icobrain ARIA can detect and grade the severity of amyloid-related imaging abnormalities. Icobrain ARIA quantifies, in a fully automated way, the extent of a potentially fatal side effect of anti-amyloid drugs known as amyloid-related imaging abnormalities (ARIA) – typically fluid buildup in the brain or blood leakage into brain tissue. Monitoring ARIA over the course of therapy allows neurologists to adjust a patient’s therapy to minimize these side effects.
Philips’ latest BlueSeal MR scanners are delivered with standardized AI-based SmartExam planning and AI-accelerated SmartSpeed protocols to image ARIA quickly and easily. Philips unique Smart Reading software [4] also allows end-to-end seamless integration of imaging protocols with the icometrix icobrain ARIA software to deliver fast, fully automated, quantitative outcomes for Alzheimer’s patients. Integrated into Philips’ healthcare informatics platform, these breakthrough AI-driven diagnostic and therapy monitoring capabilities fit seamlessly into radiology MR workflows and hospital PACS.
Speeding the differential diagnosis of multiple sclerosis
To ensure more confident diagnosis of MS, new clinical guidelines have been introduced that include a special MR imaging protocol and FLAIR* generation in Philips Advanced Visualization Workspace to simultaneously create high-quality images of white matter lesions and veins. Philips is currently the only commercial supplier of MR scanners that can perform FLAIR* imaging. icometrix icobrain ms, also seamlessly integrates on the Philips MR scanner and Philips AI Manager. It counts the number of white-matter lesions forming around veins – a characteristic highly specific to MS and it also allows for longitudinal and quantitative comparison of follow-up MRI exams, which are essential for treatment decision-making.
Philips’ latest neuroimaging solutions and icometrix’s software solutions for Alzheimer’s and MS will be available on the Philips BlueSeal 1.5T MR scanners and Philips’ 3.0T MR portfolio. The solutions will be demonstrated in the Philips booth (6730) and the icometrix booth (4903) at the Radiological Society of North America Annual Meeting (RSNA 2024, December 1-4, Chicago, USA). For more information, visit Philips at RSNA 2024.
[1] BlueSeal XE/SE and Smart Reading is not yet CE marked, not cleared in all countries, and not yet available for delivery in any country. Please consult your Philips contact person for further information.
[2] World Health Organization (WHO), Dementia Key Facts https://www.who.int/news-room/fact-sheets/detail/dementia
[3] Nichols, Emma et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, Volume 7, Issue 2, e105 - e125 https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext
[4] Philips and Icometrix have the intention to make icobrain aria software available for reselling in the USA through the Philips catalog, as well as a Smart Reading solution on MR platforms. Philips AI Manager is not intended for data interpretation or diagnosis. Availability of 3rd party algorithm may vary per market. The functionalities and benefits of the solution depend on customer-specific configuration and use. Please contact your local Philips representative for market availability.
For further information, please contact:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978 221 8919
E-mail: kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- MR technologist reviews icometrix AI report on the Philips BlueSeal MRI console
- MR technologist reviews neuro images in icometrix AI reporting tool
FAQ
What is the partnership between Philips (PHG) and icometrix announced at RSNA 2024?
How does the Philips (PHG) and icometrix AI solution help with Alzheimer's diagnosis?
What specific features does the Philips (PHG) and icometrix solution offer for MS diagnosis?
